


Bernardon
Serial No.: Div of SN 09/932,938

IN THE CLAIMS


Amend the claims as follows:

1. (Original) Biphenyl compounds substituted with an aromatic or heteroaromatic radical, characterized in that they correspond to the general formula (I) below:




in which:


Ar represents an aromatic or heteroaromatic radical chosen from:



(b)



(c)



Z being O or S,

R₁ represents -CH₃, -CH₂-OH, -OR₈ or -COR₉,


R₂ and R₃, which may be identical or different, represent H, linear or branched C₁-C₁₅ alkyl, cycloalkyl, -ZR₁₀ or a polyether radical, at least one from among R₂ and R₃ representing a linear or branched C₁-C₁₅ alkyl radical, or

R₂ and R₃, taken together, form a 5- or 6- membered ring, optionally substituted with at least one methyl and/or optionally interrupted by an oxygen or sulphur atom or by an SO or SO₂ radical,

R₄ represents H, a halogen atom, linear or branched C₁-C₂₀ alkyl, -OR₁₀, -OCOR₁₁ or a polyether radical,

R₅ represents H, a halogen atom, linear or branched C₁-C₂₀ alkyl,

-OCOR₁₁, -OR₁₂, mono- or polyhydroxyalkyl, -NO₂,



-(CH₂)_n-NHCOCH₃, -CH=CH-COR₁₃, -(CH₂)_nCOR₁₃, n being 0 to 6, -O-(CH₂)_mCOR₁₃,

O-(CH₂)_mOH, m being 1 to 12, optionally substituted aryl, optionally substituted aralkyl,


optionally substituted heteroaryl, a polyether radical or a -CH₂- polyether radical,

R₆ represents H, lower alkyl or -OR₁₀,

R₇ represents H, a halogen atom, linear or branched C₁-C₂₀ alkyl, -OR₁₀ or -OCOR₁₁ or a polyether radical,

R₈ represents H, lower alkyl, -COR₁₁,

R₉ represents H, lower alkyl, -OR₁₄ or




R₁₀ represents H or lower alkyl,

R₁₁ represents lower alkyl,

R₁₂ represents H, linear or branched C₁-C₂₀ alkyl, mono- or polyhydroxyalkyl, or optionally substituted aryl or aralkyl,

R₁₃ represents H, lower alkyl, -OR₁₀, aryl or



R₁₄ represents H, alkyl, linear or branched C₁-C₂₀ alkyl, alkenyl, mono- or

polyhydroxyalkyl, optionally substituted aryl or aralkyl, or a sugar residue,

r' and r'', which may be identical or different, represent H, OH, lower alkyl, mono- or polyhydroxyalkyl, optionally substituted aryl, an amino acid residue or a peptide residue, or r' and r'', taken together, form a heterocycle,

and the salts of the compounds of formula (I) when R₁ represents a carboxylic acid function, as well as the optical and geometrical isomers of the said compounds of formula (I).

BEST AVAILABLE COPY

2. (Original) Compounds according to Claim 1, characterized in that they are in the form of a salt of an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine.

3. (Currently Amended) Compounds according to either of Claims 1 and 2 Claim 1, characterized in that the lower alkyl radical is chosen from the group consisting of the methyl, ethyl, isopropyl, butyl, tert-butyl and hexyl radicals.

4. (Currently Amended) Compounds according to ~~any one of the preceding~~ claims Claim 1, characterized in that the linear or branched alkyl radical, when it is C₁-C₁₅, is chosen from the group consisting of the methyl, ethyl, propyl, 2-ethylhexyl, octyl and dodecyl radicals, and, when it is C₁-C₂₀, is also chosen from the hexadecyl and octadecyl radicals.

5. (Currently Amended) Compounds according to ~~any one of the preceding~~ claims Claim 1, characterized in that the monohydroxyalkyl radical is chosen from the group consisting of the hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl and 3-hydroxypropyl radicals.

6. (Currently Amended) Compounds according to ~~any one of the preceding~~ claims Claim 1, characterized in that the polyhydroxyalkyl radical is chosen from the group consisting of the 2,3-dihydroxypropyl, 2,3, 4-trihydroxybutyl and 2,3,4,5-tetrahydroxypentyl radicals and the pentaerythritol residue.

7. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the polyether radical is chosen from the group consisting of the methoxymethoxy, methoxyethoxy and methoxyethoxymethoxy radicals.

8. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the -CH₂-polyether radical is chosen from the group consisting of the methoxymethoxymethyl, ethoxymethoxymethyl and methoxyethoxymethoxymethyl radicals.

9. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the aryl radical is a phenyl radical optionally substituted with at least one halogen, a hydroxyl, a nitro function, a polyether radical or an amino function optionally protected with an acetyl group or optionally substituted with at least one C₁-C₆ lower alkyl or alkoxy.

10. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the aralkyl radical is chosen from the group consisting of benzyl and phenethyl radicals optionally substituted with at least one halogen atom, a hydroxyl, a nitro function, a polyether radical or an amino function optionally protected with an acetyl group or optionally substituted with at least one C₁-C₆ lower alkyl or alkoxy.

11. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the heteroaryl radical is chosen from the group consisting of pyridyl, furyl and thieryl radicals, optionally substituted with at least one halogen, a lower alkyl, a hydroxyl, a C₁-C₃ alkoxy, a nitro function, a polyether radical or

an amino function optionally protected with an acetyl group or optionally substituted with at least one C₁-C₆ lower alkyl or alkoxy.

12. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the alkenyl radical is chosen from the group consisting of radicals containing from 2 to 5 carbon atoms and containing one or two ethylenic unsaturation(s), in particular the allyl radical.

13. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the sugar residue is chosen from the group consisting of glucose, galactose, mannose and glucuronic acid residues.



14. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the amino acid residue is chosen from the group consisting of residues derived from lysine, from glycine or from aspartic acid.

15. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the peptide residue is chosen from the group consisting of dipeptide and tripeptide residues.

16. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that when r' and r" form a heterocycle, this is chosen from the group consisting of piperidino, morpholino, pyrrolidino and piperazino radicals, optionally substituted in position 4 with a C₁-C₆ alkyl or a mono- or polyhydroxyalkyl.


17. (Currently Amended) Compounds according to ~~any one of the preceding claims~~ Claim 1, characterized in that the halogen atom is chosen from the group consisting of fluorine, chlorine and bromine.

18. (Currently Amended) Compounds according to ~~any one of the preceding~~ claims Claim 1, characterized in that they correspond to the general formulae (II) and (III) below:



in which:

Ar represents a radical of formula (a) or (b) below:



R_1, R_4, R_5, R_6, R_7 and Z having the same meanings as those given in Claim 1,
 R_{15}, R_{16}, R_{17} and R_{18} , which may be identical or different, represent H or $-CH_3$,
and

t is 1 or 2.

19. (Currently Amended) Compounds according to ~~any one of the preceding~~ claims Claim 1, characterized in that they are taken from the group consisting of:

- 4-[4-hydroxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid, and its methyl ester,

- 4-[4-(5-hydroxypentyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid, and its methyl ester,
- 4-[4-(6-hydroxyhexyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid, and its methyl ester,
- 4-[4-(7-hydroxyheptyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,
- 4-[4-8-hydroxyoctyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,
- 4-[4-(9-hydroxynonyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,
- 4-[4-methoxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,
- 4-[4-methoxyethoxymethoxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,
- 4-[4-benzyloxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,
- 4'-(2,3-dihydroxypropoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid (racemic),
- 4'-(2,2-dimethyl[1,3]dioxolan-4-ylmethoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid (racemic),
- 4'-(2-morpholin-4-yl-ethoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

Bernardon

Serial No.: Div of SN 09/932,938

- methyl 2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylate,
- 2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-
carboxylic acid,
- 4-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 4-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 4-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 3-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 3-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 3-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 2-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 2-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 2-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2-methoxymethoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 2'-methoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 2'-propyloxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 2'-hydroxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 4'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';2',1"]terphenyl-4-carboxylic acid,
- 2'-methoxymethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-biphenyl-4'-carboxylic acid,
- 2'-hydroxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 2'-methoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 3'-methoxymethoxymethyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 3'-hydroxymethyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
- 2'-(4,4-dimethylthiochroman-7-yl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,
- 2'-(4,4-dimethylthiochroman-6-yl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,

Bernardon

Serial No.: Div of SN 09/932,938

- 2'-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2'-(3-methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

-2'-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2'-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2'-(3-propyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 3"-methyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphanyl-4"-carboxylic acid,

- 2"-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2"-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2"-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2"-propyloxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 3"-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-
[1,1';4',1"]terphenyl-4"-carboxylic acid,

Bernardon

Serial No.: Div of SN 09/932,938

- 6-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]nicotinic acid,

- 5-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]2-pyridinecarboxylic acid,

- 2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-hydroxamic acid,

- 2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-ol,

- [2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-yl]methanol,

- 2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carbaldehyde,

- 4'-methoxycarbonylmethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 4'-carboxymethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 4'-(5-ethoxycarbonylpentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 4'-(5-carboxypentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxamide,

- N-ethyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxamide,

Bernardon

Serial No.: Div of SN 09/932,938

- N,N-diethyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxamide,
- morpholin-4-yl-[2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-yl]methanone,
 - (4-hydroxyphenyl)-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxamide,
 - 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxymethyl-4'-carboxylic acid,
 - 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4,4'-dicarboxylic acid,
 - 3'-methoxymethoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
 - 3'-methoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
 - 3'-propyloxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
 - 3'-hydroxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,
 - 4'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';3',1"]terphenyl-4"-carboxylic acid,
 - 4'-(5-carboxamidopentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 3'-methoxycarbonyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 3'-carboxyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,

- 2'-(4-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2'-(4-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2'-(4-propyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4'1"]terphenyl-4"-carboxylic acid,

- 2'-(4-methoxymethoxy-5,5,8,8-teramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1"]terphenyl-4"-carboxylic acid,

- 2-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]-4-thiophenecarboxylic acid.

20. (Currently Amended) Compounds according to any one of the preceding claims Claim 1, for use as a medicinal product.

21. (Original) Compounds according to Claim 20, for use as a medicinal product intended for the treatment of dermatological complaints, dermatological complaints with an inflammatory and/or immunoallergic component of the rheumatic or respiratory type, cardiovascular complaints and ophthalmological disorders.

Claim 22 (Canceled).

23. (Currently Amended) Pharmaceutical composition, characterized in that it comprises, in a pharmaceutically acceptable support, at least one compound as defined according to ~~any one of Claims 1 to 19~~ Claim 1.

24. (Currently Amended) Composition according to Claim 23, characterized in that the concentration of said at least one compound ~~according to one of Claims 1 to 19~~ is between 0.001% and 5% by weight relative to the total weight of the composition.

25. (Currently Amended) Cosmetic composition, characterized in that it contains, in a cosmetically acceptable support, at least one compound as defined according to ~~any one of Claims 1 to 19~~ Claim 1.

26. (Currently Amended) Composition according to Claim 25, characterized in that the concentration of said at least one compound ~~according to any one of Claims 1 to 19~~ is between 0.001 and 3% by weight relative to the total weight of the composition.

27. (Currently Amended) Use of a cosmetic composition as defined according to ~~either of Claims 25 and 26~~ Claim 25, for body or hair hygiene.

28. (new) A dermatological, immunoallergic, cardiovascular and/or ophthalmological treatment method comprising administering a composition comprising a compound according to Claim 1 to a person in need of said treatment.